Serotonin reuptake inhibitor antidepressants, including selective serotonin reuptake
inhibitors (SSRIs; ie, citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and …

The field of pharmacogenomics (PGx) is gradually shifting from the reactive testing of single
genes toward the proactive testing of multiple genes to improve treatment outcomes, reduce …

Translating CYP 2D6 genotype to metabolizer phenotype is not standardized across clinical
laboratories offering pharmacogenetic (PGx) testing and PGx clinical practice guidelines …

The consistent and unambiguous description of sequence variants is essential to report and
exchange information on the analysis of a genome. In particular, DNA diagnostics critically …

Genetic polymorphisms in cytochrome P450 (CYP) genes can result in altered metabolic
activity toward a plethora of clinically important medications. Thus, single nucleotide variants …

Introduction Reporting and sharing pharmacogenetic test results across clinical laboratories
and electronic health records is a crucial step toward the implementation of clinical …

Purpose: Owing to its highly polymorphic nature and major contribution to the metabolism
and bioactivation of numerous clinically used drugs, CYP2D6 is one of the most extensively …

The goals of the Association for Molecular Pathology Clinical Practice Committee's
Pharmacogenomics (PGx) Working Group are to define the key attributes of …

The CYP2D6 gene encodes an enzyme important in the metabolism of many commonly
used medications. Variation in CYP2D6 is associated with inter-individual differences in …

Response to a drug often differs widely among individual patients. This variability is
frequently observed not only with respect to effective responses but also with adverse drug …